PL1797871T3 - Długo działający preparat o przedłużonym uwalnianiu zawierający agonistę receptora dopaminowego i sposób jego wytwarzania - Google Patents

Długo działający preparat o przedłużonym uwalnianiu zawierający agonistę receptora dopaminowego i sposób jego wytwarzania

Info

Publication number
PL1797871T3
PL1797871T3 PL05792179T PL05792179T PL1797871T3 PL 1797871 T3 PL1797871 T3 PL 1797871T3 PL 05792179 T PL05792179 T PL 05792179T PL 05792179 T PL05792179 T PL 05792179T PL 1797871 T3 PL1797871 T3 PL 1797871T3
Authority
PL
Poland
Prior art keywords
preparation
receptor agonist
release formulation
formulation containing
dopamine receptor
Prior art date
Application number
PL05792179T
Other languages
English (en)
Inventor
Luping Zhang
Original Assignee
Shandong luye pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong luye pharmaceutical co ltd filed Critical Shandong luye pharmaceutical co ltd
Publication of PL1797871T3 publication Critical patent/PL1797871T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05792179T 2004-09-21 2005-09-21 Długo działający preparat o przedłużonym uwalnianiu zawierający agonistę receptora dopaminowego i sposób jego wytwarzania PL1797871T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200410077961 2004-09-21
PCT/CN2005/001521 WO2006032202A1 (en) 2004-09-21 2005-09-21 Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof
EP05792179.3A EP1797871B1 (en) 2004-09-21 2005-09-21 Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof

Publications (1)

Publication Number Publication Date
PL1797871T3 true PL1797871T3 (pl) 2015-07-31

Family

ID=36089849

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05792179T PL1797871T3 (pl) 2004-09-21 2005-09-21 Długo działający preparat o przedłużonym uwalnianiu zawierający agonistę receptora dopaminowego i sposób jego wytwarzania

Country Status (10)

Country Link
US (2) US8691277B2 (pl)
EP (1) EP1797871B1 (pl)
JP (1) JP5081622B2 (pl)
KR (1) KR20070059161A (pl)
AU (1) AU2005287743B2 (pl)
CA (1) CA2581143C (pl)
ES (1) ES2536460T3 (pl)
HK (1) HK1107012A1 (pl)
PL (1) PL1797871T3 (pl)
WO (1) WO2006032202A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435738B2 (en) 2003-08-18 2008-10-14 Solvay Pharmaceuticals, Inc. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7405216B2 (en) 2004-08-18 2008-07-29 Solvay Pharmaceuticals, B.V. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7423040B2 (en) 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
US7964604B2 (en) 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
CA2648479C (en) * 2006-04-06 2014-10-28 Nupathe Inc. Implants for the treatment of dopamine associated states
US7786126B2 (en) 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
WO2007144421A1 (en) * 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Combination preparations comprising slv308 and a l-dopa
US8106056B2 (en) 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
WO2008009665A1 (en) * 2006-07-19 2008-01-24 Boehringer Ingelheim International Gmbh Treatment of pain
EP2291178A4 (en) * 2008-06-09 2013-07-24 Supernus Pharmaceuticals Inc PRAMIPEXOL FORMULATIONS WITH CONTROLLED RELEASE
EP2346494A2 (en) 2008-09-29 2011-07-27 Wockhardt Limited Extended release dosage form of ropinirole
FR2936710B1 (fr) * 2008-10-07 2011-01-07 Ceva Sante Animale Composition veterinaire antiprolactinique destinee aux ruminants
EP2448411A4 (en) * 2009-07-02 2012-11-28 Supernus Pharmaceuticals Inc METHOD OF TREATING A NEUROLOGICAL DISORDER
WO2011012723A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Injectable sustained release compositions comprising a pramipexole prodrug
EP2459225A1 (en) 2009-07-31 2012-06-06 Ascendis Pharma A/S Carrier linked pramipexole prodrugs
DE102010014113A1 (de) * 2010-04-07 2011-10-13 Acino Ag Freisetzungsverfahren für Implantate
CA2816288C (en) 2010-11-25 2016-01-26 Shandong Luye Pharmaceutical Co., Ltd. Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
EA201300607A8 (ru) * 2010-12-02 2014-02-28 Ратиофарм Гмбх Ионная жидкость ротиготина
US9956201B2 (en) 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
WO2018096560A1 (en) 2016-11-23 2018-05-31 Cipla Limited Long acting depot formulation for the continuous dopaminergic stimulation
US20190374534A1 (en) 2018-06-08 2019-12-12 Boehringer Ingelheim Vetmedica Gmbh Liquid pharmaceutical compositions comprising pergolide
KR102212722B1 (ko) * 2019-12-23 2021-02-08 환인제약 주식회사 로피니롤을 포함하는 마이크로스피어 및 이를 함유하는 주사제 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166800A (en) * 1977-08-25 1979-09-04 Sandoz, Inc. Processes for preparation of microspheres
JP2651320B2 (ja) 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
WO1997045105A1 (en) * 1996-05-24 1997-12-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
JPH10167968A (ja) * 1996-10-09 1998-06-23 Takeda Chem Ind Ltd マイクロパーティクルの製造法
AU4571097A (en) 1996-10-09 1998-05-05 Takeda Chemical Industries Ltd. A method for producing a microparticle
ATE203157T1 (de) * 1996-12-20 2001-08-15 Alza Corp Injizierbare depotgelzubereitung und herstellungsverfahren
JP3663271B2 (ja) * 1997-01-24 2005-06-22 シュバルツ ファルマ アクチェンゲゼルシャフト 新規の分枝鎖エステル及びその製法
ATE428371T1 (de) * 1998-07-17 2009-05-15 Pacira Pharmaceuticals Inc Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen
US6455526B1 (en) * 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
ES2245128T3 (es) * 1998-12-16 2005-12-16 Aventis Pharmaceuticals Inc. Antagonista del receptor de serotonina encapsulado en polimero biodegradable y metodo para su preparacion.
GB9828861D0 (en) 1998-12-31 1999-02-17 Danbiosyst Uk Compositions
JP4540280B2 (ja) 1999-07-09 2010-09-08 ベーテーエス ホールディング インターナショナル ベー ヴィ 光学走査装置
CN1190454C (zh) 2000-04-28 2005-02-23 田边制药株式会社 用于制备微球的方法
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10055742B4 (de) * 2000-11-10 2006-05-11 Schwarz Pharma Ag Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
IL158527A0 (en) * 2001-04-26 2004-05-12 Control Delivery Sys Inc Sustained release drug delivery system containing codrugs
AU2003295635A1 (en) * 2002-11-18 2004-06-15 Polymerix Corporation Medical devices employing novel polymers
EP1610791B1 (en) * 2003-03-31 2011-02-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen

Also Published As

Publication number Publication date
JP5081622B2 (ja) 2012-11-28
CA2581143A1 (en) 2006-03-30
WO2006032202A1 (en) 2006-03-30
US20140255488A1 (en) 2014-09-11
EP1797871B1 (en) 2015-02-25
ES2536460T3 (es) 2015-05-25
AU2005287743A1 (en) 2006-03-30
CA2581143C (en) 2015-03-31
JP2008513524A (ja) 2008-05-01
KR20070059161A (ko) 2007-06-11
US20080260846A1 (en) 2008-10-23
EP1797871A4 (en) 2012-11-28
HK1107012A1 (en) 2008-03-28
EP1797871A1 (en) 2007-06-20
US9220782B2 (en) 2015-12-29
US8691277B2 (en) 2014-04-08
AU2005287743B2 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
PL1797871T3 (pl) Długo działający preparat o przedłużonym uwalnianiu zawierający agonistę receptora dopaminowego i sposób jego wytwarzania
IL184167A0 (en) Compositions comprising anti-igf-1 receptor antibodies and methods for obtaining said antibodies
EP1482895A4 (en) AMINO ALKYL PHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS
IL169575A0 (en) Calcium-sensing receptor antagonist compounds and pharmaceutical compositions containing the same
IL183384A0 (en) Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
IL177665A0 (en) Novel pharmaceutical compositions comprising agonists of the thyroid receptor
IL183541A0 (en) Toll like receptor 3 antagonists, methods and uses
ME02643B (me) Formulacija i metod obložene tablete
EP1827389A4 (en) NANOTEHICOUS COMPOSITIONS WITH DELAYED RELEASE AND METHOD OF USE
EP1937223A4 (en) PELLET FORMULATION OF AN ALPHA1 RECEPTOR ANTAGONIST WITH DELAYED RELEASE AND METHOD OF MANUFACTURING THEREOF
IL176879A0 (en) Hydroisoindoline tachykinin receptor antagonists
AP2607A (en) Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists
AU2003238597A8 (en) Benzimidazole compounds and their use as estrogen agonists/antagonists
EP1482896A4 (en) AMINOALKYLPHOSPHONATES AND ASSOCIATED COMPOUNDS AS EDG RECEPTOR AGONISTS
EP1808446A4 (en) IL-18 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION WITH THE ANTAGONIST
AP2006003840A0 (en) Indole-2-carboxamidine derivatives as NMDA receptor antagonists
EP1912977A4 (en) EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS
IL176485A0 (en) Agonist anti-trkc antibodies and methods using same
HK1137434A1 (en) Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists
EP1845104A4 (en) AGONIST OF THE RECEIVER PAR-2
EP1520856A4 (en) ANDROGEN RECEPTOR AGONIST
GB0203412D0 (en) 5-HT 2B receptor antagonists
HUP0200057A2 (en) Dopamine d1 receptor agonist compounds, pharmaceutical compositions containing them and their use
ZA200705206B (en) Toll like receptor 3 antagonists, methods and uses
ZA200605574B (en) Hydroisoindoline tachykinin receptor antagonists